Screening of Edible Mushrooms and Extraction by Pressurized Water
Total Page:16
File Type:pdf, Size:1020Kb
1 Screening of edible mushrooms and extraction by pressurized 2 water (PWE) of 3-hydroxy-3-methyl-glutaryl CoA reductase 3 inhibitors 4 5 Alicia Gil-Ramíreza*, Cristina Clavijob, Marimuthu Palanisamya, Alejandro Ruíz-Rodrígueza, 6 María Navarro-Rubioa, Margarita Pérezb, Francisco R. Marína, Guillermo Regleroa, Cristina 7 Soler-Rivasa 8 9 aDepartment of Production and Characterization of New Foods. CIAL -Research Institute in Food Science 10 (UAM+CSIC). Madrid. Spain. 11 bCentro Tecnológico de Investigación del Champiñón de La Rioja (CTICH). Autol. Spain 12 13 * corresponding author: Alicia Gil-Ramírez. Department of Production and Characterization of New Foods. 14 CIAL -Research Institute in Food Science (UAM+CSIC). 28049 Madrid (Spain). E-mail address: 15 [email protected]. Tel: +34 910017900 16 17 18 19 20 21 22 23 24 25 1 1 ABSTRACT 2 3 The methanol/water and particularly the water extracts obtained from 26 mushroom species 4 were able to inhibit the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) activity to 5 different extent (10 to 76%). Cultivated mushrooms such as Pleurotus sp. and Lentinula 6 edodes were among the strains which showed higher HMGCR inhibitory capacities. Their 7 inhibitory properties were not largely influenced by cultivation parameters, mushroom 8 developmental stage or flush number. The HMGCR inhibitory activity of L. edodes was 9 concentrated in the cap excluding the gills while in P. ostreatus it was distributed through all 10 the different tissues. A method to obtain aqueous fractions with high HMGCR inhibitory 11 activity was optimized using an accelerated solvent extractor (ASE) by selecting 10.7 MPa 12 and 25ºC as common extraction conditions and 5 cycles of 5 min each for P. ostreatus fruiting 13 bodies and 15 cycles of 5 min for L. edodes suggesting that the potential HMGCR inhibitors 14 are different in the two selected mushrooms. 15 16 Keywords: cholesterol, HMGCoAreductase, Pleurotus ostreatus, Lentinus edodes, 17 accelerated solvent extraction (ASE) 18 19 20 21 22 23 24 25 2 1 1. INTRODUCTION 2 Coronary heart disease (CHD) is the leading cause of death in the Western world after cancer 3 according to the World Health Organization. Many studies have established that high total- 4 cholesterol and low-density lipoprotein (LDL) cholesterol levels are risk factors for CHD and 5 mortality. Several in vivo studies have demonstrated the ability of certain edible mushrooms 6 to lower cholesterol levels in serum. Species such as Pleurotus spp. (Opletal et al., 1997; 7 Bajaj et al., 1997; Bobek&Galbavy, 1999; Schneider et al., 2011), Agaricus bisporus (Jeong 8 et al., 2011), Ganoderma lucidum (Berger et al., 2004), Lentinula edodes, Grifola frondosa, 9 Flammulina velutipes (Fukushima et al., 2001), Auricularia auricular and Tremella 10 fuciformis (Cheung, 1996), among others (Roupas et al., 2012), have been investigated in 11 animals and human studies. 12 Apparently, the hypocholesterolemic effect of the mushroom fruiting bodies and several types 13 of their extracts is reached by different mechanisms of action such as impairing dietary 14 cholesterol absorption or inhibiting the endogenous cholesterol metabolism (Guillamón et al., 15 2010). Mushrooms are rich in chitin (dietary fibre) and specific -glucans which might inhibit 16 cholesterol absorption by increasing the faecal excretion of bile acids and reducing the 17 amount of serum LDL-cholesterol (Guillamón et al., 2010; Chen & Seviour, 2007). 18 Eritadenine (an adenosine analogue alkaloid) is another compound isolated from Lentinula 19 edodes (shiitake mushroom) which is able to lower cholesterol levels. This molecule inhibits 20 S-adenosylhomocysteine hydrolase and modifies the hepatic phospholipid metabolism 21 (Chibata et al., 1969, Sugiyama et al., 1995, Yamada et al., 2007). 22 According to previous reports, oyster mushrooms (Pleurotus spp.) contained lovastatin, a 23 compound able to lower cholesterol levels inhibiting 3-hydroxy-3-methyl-glutaryl CoA 24 reductase (HMGCR) (Gunde-Cimerman et al., 1993; Gunde-Cimerman&Cimerman, 1995), 25 the key-enzyme in the cholesterol metabolism. Statins are the most potent drugs available for 3 1 reducing plasma low density lipoproteins (LDL) in cholesterol concentrations (Shitara& 2 Sugiyama, 2006). However, other reports found no detectable statins levels in Pleurotus sp. 3 fruiting bodies although high HMGCR inhibition activities were recorded (Schneider et al., 4 2010; Gil-Ramirez et al., 2011). Other compounds (obtained from Ganoderma lucidum) were 5 also described as being able to impair the proper function of the enzyme (Berger et al., 2004). 6 Thus, in this work a preliminary screening of HMGCR inhibitors was carried out using 7 several edible mushroom species and varieties. The screening was also performed in 8 cultivated mushrooms harvested from cultivation rooms with different cultivation parameters 9 in an attempt to define the conditions required for the synthesis of the effective inhibitors. 10 Once the mushrooms varieties containing higher HMGCR inhibitory activity were defined, 11 they were submitted to pressurized solvent extractions (or accelerated solvent extractions, 12 ASE) in order to optimize environmentally friendly and GRAS methods able to obtain fungal 13 fractions with high HMGCR inhibitory activity to further functionalize foods with potentially 14 hypocholesterolemic properties (Chen et al., 2011). 15 16 2. MATERIAL AND METHODS 17 2.1 Biological material and samples preparation 18 Mushroom strains used in this investigation were Lentinus edodes S. (Berkeley), Cantharellus 19 cibarius (Fr.), Lactarius deliciosus (Fr.), Boletus edulis (Bull. Ex Fr.), Pleurotus ostreatus 20 (Jacq.Ex Fr.) Kummer, Agaricus bisporus L. (Imbach), Amanita caesarea (Scop. Ex Fri.) 21 Pers. Ex Schw., Morchella esculenta (Pers Ex Amans), Agaricus blazei Murill ss. (Heinem), 22 Grifola frondosa (Dicks.) Gray, Ganoderma lucidum (Curtis) P.Karst., Flammulina velutipes 23 (Curt. Ex Fr.) Singer, Pleurotus eryngii (D.C. Ex Fr.) Quel, Lyophyllum shimeji (Kawam.), 24 Morchella conica (Pers.), Agrocybe aegerita (Briganti) Singer, Auricularia judea (Bull. Ex 25 St.Amans) Berck, Amanita ponderosa Malençon & R. Heim, Craterellus cornucopioides (L. 4 1 Ex Fr.) Pers, Marasmius oreades (Bolt. Ex Fr.) Fr., Lepiota procera (Scop. Ex Fr.) Singer., 2 Pholiota nameko (T. Itô) S. Imai, Calocybe gambosa (Fr.) Donk, Hydnum repandum (Linné 3 Ex Fr.), Cantharellus lutescens (Pers.), Pleurotus pulmonarius (Fr.) Quel. 4 Fruiting bodies from wild mushrooms were purchased from a local market in Madrid (Spain). 5 The cultivable strains were grown in cultivation rooms with automatic control of cultivation 6 parameters (temperature, R.H., CO2) at CTICH (Centro Tecnológico de Investigación del 7 Champiñón de La Rioja, Autol, Spain) or at the cultivation facilities of some mushroom 8 growers belonging to the La Rioja´s mushroom association using commercially available 9 substrates depending on the mushroom specie to cultivate. Fruiting bodies were harvested at 10 the usual developmental stage prior to commercialization except in those experiments when 11 the effect of the developmental stage was studied. The recorded parameters are described in 12 Table 1. 13 Complete fruiting bodies or their separated tissues were immediately frozen, freeze-dried, 14 ground and sieved until the particle size smaller than 0.3 mm as described in Ramirez- 15 Anguiano et al. (2007) and stored at -20ºC until further use. 16 To extract the potential inhibitors from the spores allowing the breaking down of the spore 17 walls, they were first treated with methanol as described by Gunde-Cimerman et al. (1993). 18 19 2.2 Determination of HMGCoA-red inhibitors in mushrooms 20 Mushroom powders (50 mg/ml) were mixed with water, methanol/water (1:1 v/v) or 21 methanol. Suspensions were shaken in a Vortex for 1 min and centrifuged at 12000 rpm 22 (8,854 x g) for 2min (Eppendorf mini-spin, Madrid, Spain) according to the user´s manual. 23 Supernatants were used as source of HMGCR inhibitors. 24 HMGCR activity was measured using the commercial HMG-CoA Reductase Assay (Sigma, 25 Madrid) according to the user´s manual. The assay is based on the spectrophotometric 5 1 measurement of the decrease in absorbance at 340 nm, which represents the oxidation of 2 NADPH by the catalytic subunit of HMGCR in the presence of the substrate HMG-CoA 3 according to the reaction: 4 HMG-CoA + 2NADPH + 2H+ mevalonate + 2NADP+ + CoA-SH 5 Mushroom supernatants (20 l) were applied into a 96 wells-plate and their absorbance 6 change was monitorized at 37ºC using a microplate reader (Tecan Group Lt, Männedorf, 7 Switzerland). 8 Pravastatin was utilized as a control for positive inhibition. Other control samples were 9 prepared in each assay by substituting the mushroom extract by the same solvent solution 10 utilized in the extract. These controls were considered as 100% activity and tested samples 11 were referred to them as percentage of inhibition or activity. Assays were performed in 12 duplicate. 13 14 2.3 Pressurized water extractions to obtain fractions with HMGCR inhibitory activity 15 Mushroom powders (1g) were mixed with sea sand (Sigma, Madrid, Spain) (4g) and 16 submitted to pressurized solvent extraction at 1500 psi (10.68 MPa) using an accelerated 17 solvent extractor (ASE) (Dionex, ASE 350, Sunnyvale, CA, USA). Several parameters such 18 as extraction time or cycles number and temperature were changed in order to optimize the 19 extraction method to obtain fractions with